Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D.

Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.

PMID:
29691406
2.

Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Sjoberg DD, Vickers AJ, Assel M, Dahlin A, Poon BY, Ulmert D, Lilja H.

Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126-X. doi: 10.1016/j.eururo.2018.02.016. [Epub ahead of print]

PMID:
29519548
3.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

4.

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project.

Assel MJ, Gerdtsson A, Thorek DLJ, Carlsson SV, Malm J, Scardino PT, Vickers A, Lilja H, Ulmert D.

Oncotarget. 2017 Dec 5;9(5):5778-5785. doi: 10.18632/oncotarget.22981. eCollection 2018 Jan 19.

5.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, Mehta D, Murray KS, Lilja H, Ulmert D, Monette S, Scherz A, Coleman JA.

Clin Cancer Res. 2018 Feb 20. doi: 10.1158/1078-0432.CCR-17-3474. [Epub ahead of print]

PMID:
29463549
6.

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2018 Jan 31. pii: S0022-5347(18)30107-1. doi: 10.1016/j.juro.2018.01.070. [Epub ahead of print]

PMID:
29366640
7.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

8.

Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis.

Cushing K, Undvall E, Ceder Y, Lilja H, Laurell T.

Anal Chim Acta. 2018 Feb 13;1000:256-264. doi: 10.1016/j.aca.2017.11.064. Epub 2017 Dec 5.

PMID:
29289318
9.

Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.

Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Scand J Urol. 2018 Feb;52(1):27-37. doi: 10.1080/21681805.2017.1411392. Epub 2017 Dec 18.

PMID:
29254399
10.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2017 Nov 11. pii: S2405-4569(17)30258-4. doi: 10.1016/j.euf.2017.11.002. [Epub ahead of print]

PMID:
29137895
11.

Clinical-Scale Cell-Surface-Marker Independent Acoustic Microfluidic Enrichment of Tumor Cells from Blood.

Magnusson C, Augustsson P, Lenshof A, Ceder Y, Laurell T, Lilja H.

Anal Chem. 2017 Nov 21;89(22):11954-11961. doi: 10.1021/acs.analchem.7b01458. Epub 2017 Nov 9.

PMID:
29087172
12.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.

Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860-6. doi: 10.1016/j.eururo.2017.10.004. [Epub ahead of print]

PMID:
29066048
13.

Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).

Smith K, Byrne, Castaño JM, Chirlaque MD, Lilja H, Agudo A, Ardanaz E, Rodríguez-Barranco M, Boeing H, Kaaks R, Khaw KT, Larrañaga N, Navarro C, Olsen A, Overvad K, Perez-Cornago A, Rohrmann S, Sánchez MJ, Tjønneland A, Tsilidis KK, Johansson M, Riboli E, Key TJ, Travis RC.

J Clin Oncol. 2017 Apr 20;35(12):1297-1303. doi: 10.1200/JCO.2016.70.0062. Epub 2017 Mar 6.

14.

Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis.

Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, Kroll JS, McMurtry V, Ferris MJ, Engstrand L, Lilja HE, Hollister EB, Versalovic J, Neu J.

Microbiome. 2017 Mar 9;5(1):31. doi: 10.1186/s40168-017-0248-8. Review.

15.

Sutures impregnated with carbazate-activated polyvinyl alcohol reduce intraperitoneal adhesions.

Fredriksson F, Sellberg F, Bowden T, Engstrand T, Berglund D, Lilja HE.

J Pediatr Surg. 2017 Nov;52(11):1853-1858. doi: 10.1016/j.jpedsurg.2017.01.058. Epub 2017 Feb 1.

PMID:
28196659
16.

Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

Hoffmann TJ, Passarelli MN, Graff RE, Emami NC, Sakoda LC, Jorgenson E, Habel LA, Shan J, Ranatunga DK, Quesenberry CP, Chao CR, Ghai NR, Aaronson D, Presti J, Nordström T, Wang Z, Berndt SI, Chanock SJ, Mosley JD, Klein RJ, Middha M, Lilja H, Melander O, Kvale MN, Kwok PY, Schaefer C, Risch N, Van Den Eeden SK, Witte JS.

Nat Commun. 2017 Jan 31;8:14248. doi: 10.1038/ncomms14248.

17.

Risk factors for postoperative mortality in congenital diaphragmatic hernia: a single-centre observational study.

Kadir D, Lilja HE.

Pediatr Surg Int. 2017 Mar;33(3):317-323. doi: 10.1007/s00383-016-4032-9. Epub 2016 Dec 16.

18.

Patient-reported Swedish nationwide outcomes of children and adolescents with total colonic aganglionosis.

Stenström P, Brautigam M, Borg H, Graneli C, Lilja HE, Wester T.

J Pediatr Surg. 2017 Aug;52(8):1302-1307. doi: 10.1016/j.jpedsurg.2016.11.033. Epub 2016 Nov 17.

PMID:
27912975
19.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

20.

Absent ileocecal valve predicts the need for repeated step in children.

Wester T, Lilja HE, Stenström P, Pakarinen M.

Surgery. 2017 Mar;161(3):818-822. doi: 10.1016/j.surg.2016.09.011. Epub 2016 Nov 3.

PMID:
27816208
21.

Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.

Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H.

J Urol. 2017 Apr;197(4):1041-1047. doi: 10.1016/j.juro.2016.10.089. Epub 2016 Nov 1.

22.

Risk Factors for Anastomotic Strictures after Esophageal Atresia Repair: Prophylactic Proton Pump Inhibitors Do Not Reduce the Incidence of Strictures.

Donoso F, Lilja HE.

Eur J Pediatr Surg. 2017 Feb;27(1):50-55. doi: 10.1055/s-0036-1593607. Epub 2016 Oct 21.

PMID:
27769086
23.

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.

24.

Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2017 Mar;197(3 Pt 1):607-613. doi: 10.1016/j.juro.2016.09.086. Epub 2016 Sep 28.

25.

Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer.

Neal D, Lilja H.

Eur Urol. 2016 Dec;70(6):993-994. doi: 10.1016/j.eururo.2016.06.014. Epub 2016 Jun 23. No abstract available.

PMID:
27344293
26.

Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 Sep;95:224. doi: 10.1016/j.urology.2016.05.046. Epub 2016 Jun 1. No abstract available.

PMID:
27262394
27.

Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Loeb S, Lilja H, Vickers A.

Curr Opin Urol. 2016 Sep;26(5):459-65. doi: 10.1097/MOU.0000000000000316. Review.

28.

Outcome and management in infants with esophageal atresia - A single centre observational study.

Donoso F, Kassa AM, Gustafson E, Meurling S, Lilja HE.

J Pediatr Surg. 2016 Sep;51(9):1421-5. doi: 10.1016/j.jpedsurg.2016.03.010. Epub 2016 Apr 5.

PMID:
27114309
29.

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.

Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.

30.

Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

Krzyzanowska A, Lippolis G, Helczynski L, Anand A, Peltola M, Pettersson K, Lilja H, Bjartell A.

J Histochem Cytochem. 2016 May;64(5):311-22. doi: 10.1369/0022155416640466. Epub 2016 Mar 29.

31.

Author Reply.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:17-8. doi: 10.1016/j.urology.2015.12.069. Epub 2016 Mar 15. No abstract available.

PMID:
26992811
32.

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T.

PLoS One. 2016 Mar 3;11(3):e0150241. doi: 10.1371/journal.pone.0150241. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0153732.

33.

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:12-8. doi: 10.1016/j.urology.2015.12.054. Epub 2016 Feb 2.

34.

Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.

Verrill C, Cerundolo L, Mckee C, White M, Kartsonaki C, Fryer E, Morris E, Brewster S, Ratnayaka I, Marsden L, Lilja H, Muschel R, Lu X, Hamdy F, Bryant RJ.

Oncotarget. 2016 Jan 12;7(2):1107-19. doi: 10.18632/oncotarget.6689.

35.

Adhesive small bowel obstruction after laparotomy during infancy.

Fredriksson F, Christofferson RH, Lilja HE.

Br J Surg. 2016 Feb;103(3):284-9. doi: 10.1002/bjs.10072. Epub 2015 Dec 15.

PMID:
26667204
36.

Outcome of laparoscopic versus open gastrostomy in children.

Angsten G, Danielson J, Kassa AM, Lilja HE.

Pediatr Surg Int. 2015 Nov;31(11):1067-72. doi: 10.1007/s00383-015-3791-z. Epub 2015 Sep 22.

PMID:
26394873
37.

Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era.

Carlsson S, Lilja H, Vickers A.

Eur Urol Focus. 2015 Sep;1(2):149-151. doi: 10.1016/j.euf.2015.05.001. Epub 2015 Jun 9.

38.

Acoustofluidic, label-free separation and simultaneous concentration of rare tumor cells from white blood cells.

Antfolk M, Magnusson C, Augustsson P, Lilja H, Laurell T.

Anal Chem. 2015 Sep 15;87(18):9322-8. doi: 10.1021/acs.analchem.5b02023. Epub 2015 Sep 3.

PMID:
26309066
39.

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.

Timmermand OV, Ulmert D, Evans-Axelsson S, Pettersson K, Bjartell A, Lilja H, Strand SE, Tran TA.

EJNMMI Res. 2014 Dec;4(1):51. doi: 10.1186/s13550-014-0051-5. Epub 2014 Sep 19.

40.

An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.

Sullivan J, Kopp R, Stratton K, Manschreck C, Corines M, Rau-Murthy R, Hayes J, Lincon A, Ashraf A, Thomas T, Schrader K, Gallagher D, Hamilton R, Scher H, Lilja H, Scardino P, Eastham J, Offit K, Vijai J, Klein RJ.

Br J Cancer. 2015 Jun 30;113(1):166-72. doi: 10.1038/bjc.2015.199. Epub 2015 Jun 11.

41.

A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.

Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja H, Laurell T, Maeda M.

Sensors (Basel). 2015 May 22;15(5):11972-87. doi: 10.3390/s150511972.

42.

A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Braun K, Sjoberg DD, Vickers AJ, Lilja H, Bjartell AS.

Eur Urol. 2016 Mar;69(3):505-11. doi: 10.1016/j.eururo.2015.04.028. Epub 2015 May 13.

43.

miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.

Larne O, Hagman Z, Lilja H, Bjartell A, Edsjö A, Ceder Y.

Carcinogenesis. 2015 Aug;36(8):858-66. doi: 10.1093/carcin/bgv063. Epub 2015 May 12.

PMID:
25969144
44.

Genomic Predictors of Outcome in Prostate Cancer.

Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR.

Eur Urol. 2015 Dec;68(6):1033-44. doi: 10.1016/j.eururo.2015.04.008. Epub 2015 Apr 23. Review.

45.

Concurrent isolation of lymphocytes and granulocytes using prefocused free flow acoustophoresis.

Grenvall C, Magnusson C, Lilja H, Laurell T.

Anal Chem. 2015 Jun 2;87(11):5596-604. doi: 10.1021/acs.analchem.5b00370. Epub 2015 May 13.

46.

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv095. doi: 10.1093/jnci/djv095. Print 2015 Jul.

47.

A single inlet two-stage acoustophoresis chip enabling tumor cell enrichment from white blood cells.

Antfolk M, Antfolk C, Lilja H, Laurell T, Augustsson P.

Lab Chip. 2015 May 7;15(9):2102-9. doi: 10.1039/c5lc00078e.

PMID:
25824937
48.

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D.

Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.

49.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

50.

Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Vilhelmsson-Timmermand O, Santos E, Thorek DL, Evans-Axelsson S, Bjartell A, Lilja H, Larson SM, Strand SE, Tran TA, Ulmert D.

Nucl Med Biol. 2015 Apr;42(4):375-80. doi: 10.1016/j.nucmedbio.2014.12.012. Epub 2014 Dec 23.

Supplemental Content

Support Center